临床试验/NCT00585143

NCT00585143已完成1 期

Pharmacokinetics of ABT-335 and Rosuvastatin in Subjects With Normal Renal Function and Renal Impairment

AstraZeneca6 个研究点分布在 1 个国家目标入组 37 人开始时间: 2008年1月最近更新: 2012年9月28日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: AstraZeneca
入组人数: 37
试验地点: 6
主要终点: Blood concentrations of the active ingredients and metabolites of ABT-335 and rosuvastatin

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

1

Experimental

干预措施: ABT-335 (Drug)

1

Experimental

干预措施: Rosuvastatin (Drug)

结局指标

主要结局

Blood concentrations of the active ingredients and metabolites of ABT-335 and rosuvastatin

时间窗: Days 1, 8, 9, and 10

次要结局

Safety and tolerability of the study drugs(Study duration)

研究者

发起方

AstraZeneca

申办方类型

Industry

责任方

Sponsor

研究点 (6)

Loading locations...

相似试验

已完成

1 期

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal FunctionRenal Impairment

NCT01904214Novartis Pharmaceuticals16

已完成

4 期

Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal ImpairmentDisseminated Intravascular Coagulation

NCT01704001Asahi Kasei Pharma Corporation40

已完成

1 期

A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy VolunteersRenal Impairment

NCT01578928Novartis Pharmaceuticals50

已完成

1 期

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.Adverse EventsPharmacokinetic Variables

NCT00728780AstraZeneca32

已完成

1 期

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal ImpairmentRenal Insufficiency

NCT02182024Boehringer Ingelheim35